Clinical Trials
84 trialsA Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
MGC018 With or Without MGA012 in Advanced Solid Tumors
MacroGenics
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
ATL001 in Patients With Metastatic or Recurrent Melanoma
Achilles Therapeutics UK Limited
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
MODULATE
Immodulon Therapeutics Ltd
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
JAVELIN Medley
Pfizer
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Haihe Biopharma Co., Ltd.
QUAD01
University of Pittsburgh
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
Kyowa Kirin Co., Ltd.
IMM60 and Pembrolizumab in Melanoma and NSCLC
Portage Biotech
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
Evaxion Biotech A/S
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Mel63; CHAMP
University of Virginia
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Immodulon Therapeutics Ltd
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
QBiotics Group Limited
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
PIVOT IO 020
Bristol-Myers Squibb
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc
REVEAL
Nektar Therapeutics
RTX-224 Monotherapy in Patients With Solid Tumors
Rubius Therapeutics
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
Ludwig Institute for Cancer Research
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Incyte Corporation
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
PTK/ZK in Disseminated Malignant Melanoma
University Hospital Schleswig-Holstein
SYNERGY-001
Dynavax Technologies Corporation
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Oslo University Hospital
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Pfizer
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
Institut Claudius Regaud
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Array BioPharma
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
LAG-3/IMP321
Centre Hospitalier Universitaire Vaudois
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)